Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting - PubMed
6 hours ago
- #ASH 2025
- #CAR-T therapy
- #Non-viral delivery
- Novel non-viral in vivo CAR-T therapies were highlighted at the 2025 ASH Annual Meeting.
- The approach shifts from ex vivo manufacturing to direct in vivo generation of CAR-T cells.
- Non-viral delivery platforms like LNPs, VLPs, and polymeric nanoparticles were showcased.
- These technologies aim to address cost, scalability, and accessibility challenges in CAR-T therapy.
- Potential applications include treatment for autoimmune diseases and hematological malignancies.